Targeting tumour metabolism in melanoma to enhance response to immune checkpoint inhibition: A balancing act
-
Published:2024-09
Issue:
Volume:129
Page:102802
-
ISSN:0305-7372
-
Container-title:Cancer Treatment Reviews
-
language:en
-
Short-container-title:Cancer Treatment Reviews
Author:
Tiersma J.F.,
Evers B.,
Bakker B.M.,
Reijngoud D.J.,
de Bruyn M.,
de Jong S.,
Jalving M.ORCID
Reference144 articles.
1. The future of cancer treatment: Immunomodulation, CARs and combination immunotherapy;Khalil;Nat Rev Clin Oncol,2016
2. Darvin, P., Toor, S. M., Sasidharan Nair, V. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50, 1–11 (2018).
3. Dissecting the mechanisms of immune checkpoint therapy;Sharma;Nat Rev Immunol,2020
4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015
5. Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017;Ugurel;Eur J Cancer,2017